Dublin, April 02, 2026 (GLOBE NEWSWIRE) — The “Stomach Cancer Market Report 2026” has been added to ResearchAndMarkets.com’s offering. This report provides insights into market dynamics, trends, opportunities, and regional and competitor analyses.
The stomach cancer market is witnessing substantial growth, with a projected increase from USD 3.74 billion in 2025 to USD 4.26 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.9%. This expansion is due to the rising incidence of gastric cancer globally, the prevalence of Helicobacter pylori infections, the enhanced use of chemotherapy, and improvements in oncology infrastructure and diagnostic imaging techniques.
By 2030, the market is anticipated to reach USD 7.14 billion, with a CAGR of 13.8%, driven by the adoption of precision oncology and investments in novel biologics and immunotherapy pipelines.
The Helicobacter pylori infection contributes to market growth by inducing chronic inflammation that increases cancer risk. The infection’s rising prevalence, exacerbated by inadequate sanitation and living conditions, fuels market expansion. As reported by the Government of Canada, the recurrence rate of this infection stood at 19% in 2023.
Key industry players are innovating with therapies like claudin (CLDN18.2)-targeted cytolytic antibody solutions to enhance treatment precision for HER2-negative gastric cancers. In October 2024, Astellas Pharma launched Vyloy (zolbetuximab-clzb), targeting CLDN18.2-positive tumors to amplify survival rates with reduced toxicity when used alongside chemotherapy. Similarly, GSK plc. amplified its oncology portfolio by acquiring IDRx, Inc. for USD 1.15 billion to advance targeted cancer therapies.
Major contributors in the market include Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Sanofi S.A., Bristol Myers Squibb, AstraZeneca, Novartis, and others. Regionally, North America led the market in 2025, while the Asia-Pacific region is set for the fastest growth moving forward. Countries covered in this context span Australia, China, Germany, India, Japan, the UK, the USA, among others.
Reasons to Purchase:
- Obtain a global perspective with an all-encompassing report covering 16 geographies.
- Evaluate key macro factors, such as geopolitical conflicts and regulatory landscapes.
- Formulate regional and country strategies backed by localized data analysis.
- Identify investment-worthy growth segments.
- Leverage forecast data, drivers, and market trends to outperform competitors.
- Analyze end user data to better understand customer profiles.
- Benchmark against competitors focusing on market share, innovation, and brand strength.
- Assess the Total Addressable Market (TAM) and measure potential using a market attractiveness scoring system.
- Utilize comprehensive data for presentations and reports.
- Access continuously updated data along with an Excel dashboard for thorough analysis.
Report Scope
Markets Covered:
1) By Type: Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Other Types
2) By Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery
3) By Route Of Administration: Oral, Parenteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Ambulatory Surgery Centers, Hospitals And Specialty Clinics
Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Regions: Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Data Segmentation: Country and regional analysis with competitor market shares.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $4.26 Billion |
| Forecasted Market Value (USD) by 2030 | $7.14 Billion |
| Compound Annual Growth Rate | 13.8% |
| Regions Covered | Global |
The companies featured in this Stomach Cancer market report include:
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Merck and Co. Inc.
- Sanofi S.A.
- Bristol Myers Squibb Company
- AstraZeneca plc
- Novartis AG
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Amgen Inc.
- Daiichi Sankyo Company Ltd.
- BeiGene Ltd.
- Celltrion Healthcare Co. Ltd.
- Biocon Limited
- Zai Lab Limited
- MacroGenics Inc.
- Astellas Pharma Inc.
- Ipsen Group
- AbbVie Inc.
- Bayer AG
- Ono Pharmaceutical Co. Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/hheo5h
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
